Veracyte Launches Campaign to Save Lives through Early Screening for Lung Cancer
- Screen Together Campaign with Lung Cancer Initiative
Underscores Company's Commitment to Improving Outcomes for People at
High Risk of
"Lung cancer is a treatable disease, provided it is caught early," said
Through awareness activities, Screen Together aims to reach at-risk individuals where they live, work and play and inspire them to take charge of their health with the support of a friend, neighbor, colleague or family member and pledge to get screened for lung cancer at www.ScreenTogether.com.
"We are pleased to partner with
Lung cancer is the leading cause of cancer-related deaths in
"We see a tremendous opportunity to help improve care for people at high
risk of lung cancer - both as part of screening and ultimately at other
points in the lung cancer continuum," said
About Screen Together
Screen Together is an initiative that encourages those at risk for lung cancer to get screened along with a friend or loved one who may also be at risk. Through awareness activities, Screen Together aims to reach at-risk individuals where they live, work and play and inspire them to take charge of their health with the support of a friend, neighbor, colleague or family member and pledge to get screened for lung cancer at www.ScreenTogether.com.
In
About Veracyte
About Lung Cancer Initiative of
As the state's leading non-profit organization supporting lung cancer
research and education, the Lung Cancer Initiative of
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, our plans with respect to expanding the program's reach and the potential benefits of our Percepta test. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: demand for our tests, the applicability of clinical results to actual outcomes; laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; our ability to successfully achieve and maintain adoption of and reimbursement for our products; the amount by which use of our products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the occurrence and outcomes of clinical studies; the timing and publication of clinical study results; and other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.
1
2 Ibid.
3 2017
View source version on businesswire.com: http://www.businesswire.com/news/home/20170919005608/en/
Media:
tracy.morris@veracyte.com
or
Investors:
jackie@veracyte.com
Source:
News Provided by Acquire Media